Segal G M, Duckert L G
Cancer. 1986 Mar 15;57(6):1089-91. doi: 10.1002/1097-0142(19860315)57:6<1089::aid-cncr2820570603>3.0.co;2-r.
Mechlorethamine, when administered in massive doses (0.6-1.5 mg/kg) to cancer patients in several early studies, caused severe irreversible hearing loss. There have been no reports of ototoxicity with doses of 0.4 mg/kg or less. The authors describe a 36-year-old man who developed profound sensorineural hearing loss during his first cycle of MOPP chemotherapy for Hodgkin's disease. Cyclophosphamide was substituted for mechlorethamine in subsequent cycles and his hearing deficit resolved. This is the first reported case of reversible ototoxicity associated with currently recommended doses of mechlorethamine.
在早期的多项研究中，当给癌症患者大剂量（0.6 - 1.5毫克/千克）使用氮芥时，会导致严重的不可逆听力丧失。尚无关于0.4毫克/千克及以下剂量耳毒性的报告。作者描述了一名36岁男性，他在接受霍奇金病的MOPP化疗的第一个周期中出现了严重的感音神经性听力丧失。在随后的周期中，用环磷酰胺替代了氮芥，他的听力缺陷得以解决。这是首例报告的与当前推荐剂量氮芥相关的可逆性耳毒性病例。
